Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R Cereda

Showing results (11-20 of 18) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 18 results.
Journal of Medicinal Chemistry|January 6, 1995
New antianginal nitro esters with reduced hypotensive activity. Synthesis and pharmacological evaluation of 3-[(nitrooxy)alkyl]-2H-1,3-benzoxazin-4(3H)-onesF Benedini, G Bertolini, R Cereda, et al.
Journal of Cardiovascular Pharmacology|January 1, 1995
Protective effects of ITF 296 in the isolated rabbit heart subjected to global ischemiaG Rossoni, F Berti, M Bernareggi, et al.
Peptides|November 1, 1986
Protective effect of CR 1409 (cholecystokinin antagonist) on experimental pancreatitis in rats and miceF Makovec, M Bani, R Cereda, et al.
Journal of Cardiovascular Pharmacology|January 1, 1995
The new nitroderivative ITF 296 improves collateral blood flow in a canine model of coronary thrombosisM G Trivella, G Barsotti, R Cereda, et al.
Arzneimittel-Forschung|June 1, 1987
Pharmacological characterisation of a new potent and specific nonpolypeptidic cholecystokinin antagonistI Setnikar, M Bani, R Cereda, et al.
Arzneimittel-Forschung|November 1, 1987
Pharmacological properties of lorglumide as a member of a new class of cholecystokinin antagonistsF Makovec, M Bani, R Cereda, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 28, 2020
Corrections to "Phase I/IIa study evaluating the safety, efficacy, pharmacokinetics, and pharmacodynamics of lucitanib in advanced solid tumors"J-C Soria, F DeBraud, R Bahleda, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 7, 2014
Phase I/IIa study evaluating the safety, efficacy, pharmacokinetics, and pharmacodynamics of lucitanib in advanced solid tumorsJ-C Soria, F DeBraud, R Bahleda, et al.
Pageof 2

Showing results (11-20 of 18) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 18 results.
Journal of Medicinal Chemistry|January 6, 1995
New antianginal nitro esters with reduced hypotensive activity. Synthesis and pharmacological evaluation of 3-[(nitrooxy)alkyl]-2H-1,3-benzoxazin-4(3H)-onesF Benedini, G Bertolini, R Cereda, et al.
Journal of Cardiovascular Pharmacology|January 1, 1995
Protective effects of ITF 296 in the isolated rabbit heart subjected to global ischemiaG Rossoni, F Berti, M Bernareggi, et al.
Peptides|November 1, 1986
Protective effect of CR 1409 (cholecystokinin antagonist) on experimental pancreatitis in rats and miceF Makovec, M Bani, R Cereda, et al.
Journal of Cardiovascular Pharmacology|January 1, 1995
The new nitroderivative ITF 296 improves collateral blood flow in a canine model of coronary thrombosisM G Trivella, G Barsotti, R Cereda, et al.
Arzneimittel-Forschung|June 1, 1987
Pharmacological characterisation of a new potent and specific nonpolypeptidic cholecystokinin antagonistI Setnikar, M Bani, R Cereda, et al.
Arzneimittel-Forschung|November 1, 1987
Pharmacological properties of lorglumide as a member of a new class of cholecystokinin antagonistsF Makovec, M Bani, R Cereda, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 28, 2020
Corrections to "Phase I/IIa study evaluating the safety, efficacy, pharmacokinetics, and pharmacodynamics of lucitanib in advanced solid tumors"J-C Soria, F DeBraud, R Bahleda, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 7, 2014
Phase I/IIa study evaluating the safety, efficacy, pharmacokinetics, and pharmacodynamics of lucitanib in advanced solid tumorsJ-C Soria, F DeBraud, R Bahleda, et al.
Pageof 2